A comparison of methods of plasmapheresis for the treatment of late antibody mediated rejection in kidney transplant recipients

被引:2
|
作者
Caliskan, Yasar [1 ,2 ]
Mirioglu, Safak [2 ,3 ]
Dirim, Ahmet Burak [2 ]
Ozluk, Yasemin [4 ]
Yegit, Ozan [2 ]
Aksoy, Elif [2 ]
Safak, Seda [2 ]
Guller, Nurana [2 ]
Demir, Erol [2 ]
Artan, Ayse Serra [2 ]
Oto, Ozgur Akin [2 ]
Besisik, Sevgi [5 ]
Yazici, Halil [2 ]
Turkmen, Aydin [2 ]
Lentine, Krista L. [1 ]
机构
[1] St Louis Univ, Sch Med, Ctr Abdominal Transplantat, 3660 Vista Ave, St Louis, MO 63110 USA
[2] Istanbul Univ, Istanbul Sch Med, Div Nephrol, Istanbul, Turkey
[3] Bezmialem Vakif Univ, Div Nephrol, Sch Med, Istanbul, Turkey
[4] Istanbul Univ, Istanbul Sch Med, Dept Pathol, Istanbul, Turkey
[5] Istanbul Univ, Istanbul Sch Med, Div Hematol, Istanbul, Turkey
关键词
antibody mediated rejection; kidney transplantation; plasmapheresis; rejection; HUMORAL REJECTION; ALLOGRAFT-REJECTION; PLASMA-EXCHANGE; RITUXIMAB; IMMUNOADSORPTION; OUTCOMES; THERAPY; RESCUE;
D O I
10.1111/1744-9987.13937
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction We compared the outcomes associated with plasma exchange (PE), double filtration plasmapheresis (DFPP), or immunoadsorption (IA) in the treatment of late antibody mediated rejection (AMR). Methods Sixty-nine kidney transplantation (KTx) recipients with late AMR were retrospectively categorized according to management with PE (n = 30), DFPP (n = 22) or IA (n = 17). Allograft loss was compared across treatment groups by Kaplan-Meier analysis and Cox regression. Results Study groups were similar regarding age, sex, donor type, kidney function, donor specific antibodies, and post-KTx follow-up time. Five-year graft survival trended higher with IA (70.6%) compared to PE (36.7%) and DFPP (27.3%) (p = 0.06). In multivariate Cox regression, baseline eGFR (HR per ml/min/1.73 m(2) [95% CI]; 0.96 [0.94-0.99]), rituximab use (HR [95% CI]; 0.42 [0.21-0.84]), interstitial inflammation (i) (HR [95% CI]; 2.05 [1.13-3.69]), and transplant glomerulopathy (cg) (HR [95% CI]; 1.46 [1.13-1.87]) were associated with graft loss. Conclusion These results motivate the need for continued assessment of rituximab and plasmapheresis in larger studies.
引用
收藏
页码:428 / 434
页数:7
相关论文
共 50 条
  • [1] A Comparison of Plasmapheresis Methods in the Treatment of Late Antibody Mediated Rejection
    Caliskan, Y.
    Yazici, H.
    Dirim, A. B.
    Aksoy, E.
    Safak, S.
    Garayeva, N.
    Mirioglu, S.
    Yegit, O.
    Oto, O. A.
    Ozluk, Y.
    Besisik, S.
    Turkmen, A.
    Lentine, K.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2021, 21 : 451 - 451
  • [2] Plasmapheresis for the Treatment of Antibody-Mediated Rejection in Lung Transplant Recipients
    Dordevic, M.
    Sandhaus, T.
    Leuze, M.
    Steinke, T.
    Kirov, H.
    Rummler, S.
    Steinert, M.
    Faerber, G.
    Doenst, T.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2017, 36 (04): : S401 - S402
  • [3] Treatment of late antibody mediated rejection in renal transplant recipients
    Galliford, J.
    Shiu, K.
    Chan, K.
    England, M.
    Cook, T.
    McLean, A.
    Warrens, A.
    Taube, D.
    Dorling, A.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2008, 8 : 442 - 443
  • [4] To Treat or Not To Treat: Late Antibody Mediated Rejection in Kidney Transplant Recipients
    Diskin, D.
    Williams, T.
    Reed, R.
    Locke, J.
    Mannon, R.
    Gaston, R.
    Kumar, V.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2014, 14 : 436 - 436
  • [5] To Treat or Not To Treat: Late Antibody Mediated Rejection in Kidney Transplant Recipients
    Diskin, D.
    Williams, T.
    Reed, R.
    Locke, J.
    Mannon, R.
    Gaston, R.
    Kumar, V.
    TRANSPLANTATION, 2014, 98 : 436 - 436
  • [6] Treatment of late antibody mediated rejection with IVIG and plasmapheresis in renal transplant patients
    Ebcioglu, Zeynep A.
    Vasilescu, Elena R.
    Crew, Russell J.
    Dube, Geoffrey K.
    Russo, Mark J.
    Cohen, David J.
    Hardy, Mark A.
    Suciu-Foca, Nicole
    Ratner, Lloyd E.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2008, 8 : 581 - 581
  • [7] A Randomized Trial Comparing Imlifidase to Plasmapheresis in Kidney Transplant Recipients With Antibody-Mediated Rejection
    Halleck, Fabian
    Boehmig, Georg A.
    Couzi, Lionel
    Rostaing, Lionel
    Einecke, Gunilla
    Lefaucheur, Carmen
    Legendre, Christophe
    Montgomery, Robert
    Hughes, Peter
    Chandraker, Anil
    Wyburn, Kate
    Halloran, Phil
    Maldonado, Angela Q.
    Sjohoelm, Kristoffer
    Runstroem, Anna
    Lefevre, Paola
    Tollemar, Jan
    Jordan, Stanley
    CLINICAL TRANSPLANTATION, 2024, 38 (07)
  • [8] The Outcomes of Late Onset Antibody Mediated Rejection in Kidney Transplant Recipients.
    Park, Jae Berm
    Kim, Young Hoon
    Kwon, Seog-Woon
    Jung, Joo Hee
    Kim, Song-Cheol
    Han, Duck Jong
    AMERICAN JOURNAL OF TRANSPLANTATION, 2010, 10 : 397 - 397
  • [9] Tocilizumab for the treatment of chronic antibody mediated rejection in kidney transplant recipients
    Khairallah, Pascale
    Robbins-Juarez, Shelief
    Patel, Shefali
    Shah, Vaqar
    Toma, Katherine
    Fernandez, Hilda
    Dube, Geoffrey K. K.
    King, Kristen
    Mohan, Sumit
    Husain, Syed Ali
    Morris, Heather
    Crew, Russell John
    CLINICAL TRANSPLANTATION, 2023, 37 (01)
  • [10] ANTIBODY-MEDIATED REJECTION IN LUNG TRANSPLANT RECIPIENTS TREATED WITH PLASMAPHERESIS
    Djordjevic, M.
    Sandhaus, T.
    Steinke, T.
    Leuze, M.
    Kirov, H.
    Faerber, G.
    Breuer, M.
    Steinert, M.
    Rummler, S.
    Doenst, T.
    TRANSPLANT INTERNATIONAL, 2017, 30 : 11 - 12